Keywords: Endo, ProStrakan, Fortesa, Licensing
Endo to buy US rights to ProStrakan’s Fortesta for up to $210 million
Article | 26 August 2009
US drugmaker Endo has signed an agreement with UK-based ProStrakan Group for the exclusive right to commercialize Fortesta (testosterone gel) 2% ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
